The Translational Health Science and Technology Institute (THSTI), an independent organization within the Department of Biotechnology, Ministry of Science and Technology of India, and Miltenyi Biotec, a well-known provider of biomedical solutions, have established a strategic cooperation. A formal Letter of Intent establishing this partnership was presented at THSTI’s 15th Foundation Day celebrations.
This collaboration aims to further the development of novel cell and gene therapies (CGT) that target sickle cell disease and cancer. The goals of both organizations are to improve research, development, and application in these important fields by utilizing their unique capabilities. Through the partnership, THSTI’s research capabilities and Miltenyi Biotec’s biomedical technology expertise will be combined to address the growing need for efficient treatments in these difficult medical domains.
A number of important areas are expected to be covered by this relationship, including joint research projects, training programs, capacity building, and technology transfer. By converting cutting-edge research into practical medical remedies, these initiatives hope to improve treatment outcomes for people with significant unmet medical needs.
Sivakumar Natarajan, Managing Director (Interim) of Miltenyi Biotec India; Dr. Prudwidhar S., Director of Country Medical Affairs at Miltenyi Biotec; and Prof. Ganesan Karthikeyan, Executive Director of BRIC-THSTI, all signed the Letter of Intent. Dr. Rajesh S. Gokhale, Director General of BRIC and Secretary of the Department of Biotechnology, and Dr. Jitendra Singh, Minister of State (IC) for the Ministry of Science and Technology, Government of India, observed the signing.
Sivakumar Natarajan emphasized the value of Miltenyi Biotec’s technology by pointing out that their cell products are used to treat over 10,000 patients a year. He underlined that creating innovative therapeutics for people with illnesses for whom there are presently no effective treatments is made possible by the collaboration with THSTI.
Prof. Ganesan Karthikeyan was enthusiastic about the partnership and described it as a significant step forward for THSTI’s translational research initiatives. He stated that the collaboration leverages the institute’s experience in clinical trials and cutting-edge research to provide the Indian public with cutting-edge cancer treatments that are both accessible and inexpensive.Viewing this alliance as a strategic effort to enhance its influence in the Indian biomedical sector, Miltenyi Biotec began operations in India in February 2024, following the BioAsia Summit in Hyderabad. It is anticipated that the partnership with THSTI will propel noteworthy progress in the fields of gene and cell therapy research, which could revolutionize the approach to treating sickle cell disease and cancer.
SOURCE:
BIO SPECTRUM INDIA
